ReviewPurinergic signalling2018
The involvement of purinergic signalling in obesity.
Review in Purinergic signalling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- AMetabolites · 2026Article
- Adipose Tissue and Central Nervous System Crosstalk: Roles in Pain and Cognitive Dysfunction.Biomedicines · 2025Review
- Cell Type-Specific Expression of Purinergic P2X Receptors in the Hypothalamus.International journal of molecular sciences · 2025Review
- Implication of xanthine oxidoreductase in oxidative stress-related chronic diseases.Frontiers in endocrinology · 2025Review
- Article
- Transcutaneous auricular vagus nerve stimulation as a potential novel treatment for polycystic ovary syndrome.Scientific reports · 2023Review
- Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes.Frontiers in pharmacology · 2023Article
- Bioinformatics analysis reveals the landscape of immune cell infiltration and novel immune-related biomarkers in moyamoya disease.Frontiers in genetics · 2023Article
- The Interplay of Endothelial P2Y Receptors in Cardiovascular Health: From Vascular Physiology to Pathology.International journal of molecular sciences · 2022Review
- Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.Current opinion in pharmacology · 2022Review
- ZoomForward2022: European Congress on Obesity.Obesity facts · 2022Article
- Mechanism of insulin resistance in obesity: a role of ATP.Frontiers of medicine · 2021Review
- Purinergic signaling in diabetes and metabolism.Biochemical pharmacology · 2021Review
- Metabolic Changes Induced by Purinergic Signaling: Role in Food Intake.Frontiers in pharmacology · 2021Review
- ADP Induces Blood Glucose Through Direct and Indirect Mechanisms in Promotion of Hepatic Gluconeogenesis by Elevation of NADH.Frontiers in endocrinology · 2021Article
- The P2XFrontiers in molecular neuroscience · 2021Article
- The Role of a Selective P2YBioMed research international · 2020Article
- P2YFrontiers in endocrinology · 2020Article
- P2X7 Receptor in the Management of Energy Homeostasis: Implications for Obesity, Dyslipidemia, and Insulin Resistance.Frontiers in endocrinology · 2020Review
- Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a growing worldwide health problem, with an alarming increasing prevalence in developed countries, caused by a dysregulation of energy balance. Currently, no wholly successful pharmacological treatments are available for obesity and related adverse consequences. In recent years, hints obtained from several experimental animal models support the notion that purinergic signalling, acting through ATP-gated ion channels (P2X), G protein-coupled receptors (P2Y) and adenosine receptors (P1), is involved in obesity, both at peripheral and central levels. This review has drawn together, for the first time, the evidence for a promising, much needed novel therapeutic purinergic signalling approach for the treatment of obesity with a 'proof of concept' that hopefully could lead to further investigations and clinical trials for the management of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.